Boston Herald logo
CBS News logo
ABC News logo
3 articles
·14d

FDA Approves Moderna's New Low-Dose COVID-19 Vaccine with Usage Restrictions

The FDA has approved Moderna's mNexspike vaccine for specific high-risk groups, marking a shift in COVID-19 vaccination strategy.


Overview

A summary of the key points of this story verified across multiple sources.

The FDA has approved Moderna's new low-dose COVID-19 vaccine, mNexspike, for adults 65 and older and those aged 12-64 with health conditions. This vaccine is not a replacement for the existing Spikevax but offers a lower dose option. The approval reflects a cautious approach amid skepticism from health officials. The decision follows a study showing mNexspike's safety and effectiveness. Moderna plans to provide both vaccine options this fall, despite recent funding cuts for pandemic flu vaccine development by the Trump administration.

Content generated by AI—learn more or report issue.

Pano Newsletter

Get both sides in 5 minutes with our daily newsletter.

Analysis

Compare how each side frames the story — including which facts they emphasize or leave out.

There are not enough sources from this perspective to provide an analysis.

Articles (3)

Compare how different news outlets are covering this story.

LeftCenterRight
ABC News
CBS News
Boston Herald
FDA approves Moderna's new lower-dose COVID-19 vaccine
ABC NewsABC News·14d·
Center
This outlet is balanced or reflects centrist views.

"…The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines."

FDA approves Moderna’s new lower-dose COVID-19 vaccine
Boston HeraldBoston Herald·14d·
Leans Right
This outlet slightly leans right.

"…The approval adds an important new tool to help protect people at high risk of severe disease from COVID-19."

FAQ

A list of follow-up questions readers often ask about this story.